The anti-hyperlipidemic action of MGO is associated with camphene.

The placebo group (A) was administered 1 ml carrier alone. The Triton WR-1339 group (B) was administered 1 ml carrier and one h later 1 ml of Triton WR-1339 (200 mg/kg). Animals in (C) and (D) received Mixture A and Mixture B, respectively, in 1 ml carrier and one hour later received Triton WR-1339. Mixture A consisted of α-pinene, β-pinene, myrcene, β-caryophyllene and linalool; and Mixture B consisted of Mixture A+camphene. The constituents in Mixtures A and B were present at concentrations identical to those contained in the 4% MGO dose. The percent change caused by Mixture A and B treatments is expressed relative to measurement in the group of Triton WR-1339-treated rats (B), which was defined as 100%. The values represent mean ± SD of six rats. Significantly different values were obtained in Mixture B-treated rats compared to Triton WR-1339-treated rats with p***) by the Student-Newmann-Keuls test. Values of Mixture A-treated rats vs Triton WR-1339-treated rats were non significant, ns (p>0.05).